<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100513</url>
  </required_header>
  <id_info>
    <org_study_id>Hanan Soliman</org_study_id>
    <nct_id>NCT03100513</nct_id>
  </id_info>
  <brief_title>PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy</brief_title>
  <official_title>Randomized Trial Comparing The Efficacy of PEG (Polyethylene Glycol) Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sherief Abd-Elsalam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current standard of care for patients with HE includes non-absorbable
      disaccharides(lactulose);The chemical name for lactulose is
      4-O-Î²-D-galactopyranosyl-D-fructofuranose.The exact mode of action by lactulose is thought to
      be the conversion to lactic acid and acetic acid by colonic bacteria resulting in
      acidification of the gut lumen. This favors conversion of ammonia (NH3) to ammonium (NH4+),
      which is relatively membrane impermeable; therefore, less ammonia is absorbed by the colon.
      Gut acidification inhibits ammoniagenic coliform bacteria, leading to increased levels of
      nonammoniagenic lactobacilli. Nonabsorbable disaccharides also work as a cathartic, clearing
      the gut of ammonia before it can be absorbed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polyethylene glycol electrolyte solution (PEG) is a laxative solution that increases the
      amount of water in the intestinal tract to stimulate bowel movements. It is used safely to
      clean the bowel before colonoscopy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 or more in HE grade improvement at 24 hours</measure>
    <time_frame>24 hours</time_frame>
    <description>HE grade improvement at 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to HE resolution</measure>
    <time_frame>2 weeks</time_frame>
    <description>Time to Hepatic encephalopathy resolution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall length of stay</measure>
    <time_frame>2 weeks</time_frame>
    <description>Overall length of stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Lactulose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polyeyhylene Glychol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polyethylene Glycol 3sachets if patient &lt;75Kg over 3 hours or 4 sachets if patient &gt;75Kg over 4 hours dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose</intervention_name>
    <description>(lactulose) (20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate</description>
    <arm_group_label>Lactulose</arm_group_label>
    <other_name>Duphlac, lactulose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene Glycol</intervention_name>
    <description>PEG as single dose of (3sachets if patient &lt;75Kg over 3 hours or 4 sachets if patient &gt;75Kg over 4 hours) dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water).</description>
    <arm_group_label>Polyeyhylene Glychol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult Patients with Overt Hepatic Encephalopathy.

        Exclusion Criteria:

          1. Patients with active GIT bleeding.

          2. Patients with history of bowel obstruction, perforation.

          3. Patients with history of allergy to PEG.

          4. Treatment with rifaximin or neomycin in the previous 7 days.

          5. Patients with major psychiatric illness.

          6. Patients receiving benzodiazepines and narcotics.

          7. Patients with compromised renal.

          8. Patients receiving medications highly bound to plasma proteins eg. Warfarin.

          9. Pregnant or lactating women.

         10. Fulminant hepatic failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanan Soliman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tanta University Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amany Abd El-Rahim Abdin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tanta university Faculty of Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samah Mosaad Soliman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tanta University Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hala Hany Shehata, Msc</last_name>
    <role>Study Chair</role>
    <affiliation>Tanta University Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherief Abd-Elsalam, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tanta University Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherief Abd-Elsalam, MD</last_name>
    <phone>00201095159522</phone>
    <email>Sheriefabdelsalam@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tropical medicine dept.-Tanta university hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherief Abd-Elsalam</last_name>
      <email>Sherif_tropical@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sherief Abd-Elsalam</investigator_full_name>
    <investigator_title>Clinical Ass Prof. Hepatology and Gastroenterology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

